1184 related articles for article (PubMed ID: 33107944)
1. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
[TBL] [Abstract][Full Text] [Related]
2. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
3. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
[TBL] [Abstract][Full Text] [Related]
4. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
[TBL] [Abstract][Full Text] [Related]
6. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
[TBL] [Abstract][Full Text] [Related]
7. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
[TBL] [Abstract][Full Text] [Related]
8. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ;
Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203
[TBL] [Abstract][Full Text] [Related]
9. Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
Xue Y; Hu Z; Jing Y; Wu H; Li X; Wang J; Seybert A; Xie X; Lv Q
J Clin Pharm Ther; 2020 Oct; 45(5):1076-1086. PubMed ID: 32627223
[TBL] [Abstract][Full Text] [Related]
10. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
[TBL] [Abstract][Full Text] [Related]
11. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries.
Bianco M; Careggio A; Biolè CA; Quadri G; Quiros A; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solè A; Liebetrau C; Manzano-Fernàndez S; Boccuzzi G; Henriques JPS; Spirito A; Templin C; Wilton SB; Velicki L; Correia L; Rognoni A; Ugo F; Nunez-Gil I; Fujii T; Durante A; Song X; Kawaji T; Alexopoulos D; Huczek Z; Gonzàlez Juanatey JR; Nie SP; Kawashiri MA; Morbiducci U; Dominguez-Rodriguez A; Destefanis P; Luciano A; De Ferrari GM; Varbella F; Montagna L; D'Ascenzo F; Cerrato E
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1171-1182. PubMed ID: 34224052
[TBL] [Abstract][Full Text] [Related]
13. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
14. Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction.
Sim DS; Jeong MH; Kim HS; Gwon HC; Seung KB; Rha SW; Chae SC; Kim CJ; Cha KS; Park JS; Yoon JH; Chae JK; Joo SJ; Choi DJ; Hur SH; Seong IW; Cho MC; Kim DI; Oh SK; Ahn TH; Hwang JY;
J Cardiol; 2019 Feb; 73(2):142-150. PubMed ID: 30509351
[TBL] [Abstract][Full Text] [Related]
15. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Sachdeva A; Mutyala R; Mantri N; Zhu S; McNulty E; Solomon M
J Interv Cardiol; 2023; 2023():1147352. PubMed ID: 37251366
[TBL] [Abstract][Full Text] [Related]
16. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
[TBL] [Abstract][Full Text] [Related]
17. Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention.
Venetsanos D; Träff E; Erlinge D; Hagström E; Nilsson J; Desta L; Lindahl B; Mellbin L; Omerovic E; Szummer KE; Zwackman S; Jernberg T; Alfredsson J
Heart; 2021 Jul; 107(14):1145-1151. PubMed ID: 33712510
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Potent Oral P2Y
Ma S; Li Z; Yu P; Song H; Jiang Z; Li Y; Han Y
Cardiovasc Drugs Ther; 2020 Apr; 34(2):199-208. PubMed ID: 32006144
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
